혈액투석중인 만성 신부전 환자에서 혈청 Neopterin 농도에 관한 연구 = A Study of Serum Neopterin Levels in Chronic Renal Failure Patients Undergoing Hemodialysis혈액투석중인 만성 신부전 환자에서 혈청 Neopterin 농도에 관한 연구

다국어 초록 (Multilingual Abstract)

Neopterin is a low-molecular-weight product released by human macrophages upon stimulation with interferon gamma. It permits the quantification of the level of cellulalr immune activation in vivo. We measured the level of serum neopterin and creatinine concentrations in 20 patients before and after hemodialysis in order to test whether hemodialysis induces specific activation of the T-lymphocyte macrophage axis. The results were as follows: 1) In normal adults, the serum neopterin level was 6.7±1.3 nmol/L with no sex difference. 2) In 20 hemodialysis patients, the serum neopterin level before hemodialysis was 246.2±97.6 nmol/L and increased significantly compared to normal adults (p<0.001). 3) In 20 hemodialysis patients, the serum neopterin level was 163.0±76.7 nmol/L after hemodialysis and decreased significantly (p<0.001), the neopterin/creatinine ratio was 25.4±14.7, 32.8±23.7 before and after hemodialysis, respectively, and there was no significant difference between both groups. 4) In groups of short-term hemodialysis (less than three months), the serum neopterin level was 248.4±100.6, 181.7±91.2nmol/L before and after hemodialysis, respectively. In groups of long-term hemodialysis (more than one year), the neopterin level was 244.0±99.9, 144.2±57.6 nmol/L before and after hemodialysis, respectively, and decreased significantly after hemodialysis in both groups (p<0.001), and there was no significant difference between both groups. 5) In 12 male hemodialysis patients, the serum neopterin level was 226.4±97.6, 145.5±60.5nmol/L before and in after hemodialysis, respectively, and in eight female hemodialysis patients, the serum neopterin level was 275.9±96.0, 189.1±94.4 nmol/L before and after hemodialysis, respectively, and decreased significantly in both groups (p<0,05, respectively). There was no significant difference between both groups.Neopterin is a low-molecular-weight product released by human macrophages upon stimulation with interferon gamma. It permits the quantification of the level of cellulalr immune activation in vivo. We measured the level of serum neopterin and creatinine concentrations in 20 patients before and after hemodialysis in order to test whether hemodialysis induces specific activation of the T-lymphocyte macrophage axis. The results were as follows: 1) In normal adults, the serum neopterin level was 6.7±1.3 nmol/L with no sex difference. 2) In 20 hemodialysis patients, the serum neopterin level before hemodialysis was 246.2±97.6 nmol/L and increased significantly compared to normal adults (p<0.001). 3) In 20 hemodialysis patients, the serum neopterin level was 163.0±76.7 nmol/L after hemodialysis and decreased significantly (p<0.001), the neopterin/creatinine ratio was 25.4±14.7, 32.8±23.7 before and after hemodialysis, respectively, and there was no significant difference between both groups. 4) In groups of short-term hemodialysis (less than three months), the serum neopterin level was 248.4±100.6, 181.7±91.2nmol/L before and after hemodialysis, respectively. In groups of long-term hemodialysis (more than one year), the neopterin level was 244.0±99.9, 144.2±57.6 nmol/L before and after hemodialysis, respectively, and decreased significantly after hemodialysis in both groups (p<0.001), and there was no significant difference between both groups. 5) In 12 male hemodialysis patients, the serum neopterin level was 226.4±97.6, 145.5±60.5nmol/L before and in after hemodialysis, respectively, and in eight female hemodialysis patients, the serum neopterin level was 275.9±96.0, 189.1±94.4 nmol/L before and after hemodialysis, respectively, and decreased significantly in both groups (p<0,05, respectively). There was no significant difference between both groups.